A Predictive Patient-Level Surrogacy Model Between Progression-Free Survival (PFS) and Overall Survival (OS) in Patients With Pre-Treated Advanced or Metastatic (A/M) Non-Small-Cell Lung Cancer (NSCLC) With a KRASG12C Mutation
Author(s)
Berardi A1, Maciel D2, Cope S3, Mastikhina L2, Lee A4
1Precision AQ, London, LON, UK, 2Precision AQ, Vancouver, BC, Canada, 3Precision AQ, VANCOUVER, Canada, 4Bristol Myers Squibb, Uxbridge, LON, UK
Presentation Documents
OBJECTIVES: Cost-effectiveness analyses for health technology assessment require OS predictions over a lifetime horizon. When OS data are unavailable and trial-level relationship between surrogate endpoints and OS cannot be established or is not credible, individual-level surrogacy relationships can be used.
The study objective is to estimate and validate a predictive individual-level surrogacy model between PFS and OS in pre-treated patients with KRASG12C-mutated a/m-NSCLC.METHODS: Patient-level surrogacy of PFS and OS was evaluated based on the joint frailty-copula model described by Emura-2017. Sensitivity analyses considered individual-level frailty factors. The model was fit to PFS and OS data from KRYSTAL-1 Cohort A, a Phase 2 single-arm trial investigating adagrasib in the target population. Covariate selection was based on clinical expert opinion from previous analyses of KRYSTAL-1. Patient-specific OS was simulated using the covariate-adjusted failure function, conditional on progression status at the observed PFS event/censor time. Patients alive when <5% of the sample was at risk of progression were censored, reducing reliance on event-free PFS tails.
The model internal validity was tested by replicating KRYSTAL-1 OS from KRYSTAL-1 PFS. For external validation, the OS of the docetaxel arm of SAPPHIRE, an RCT in patients with pretreated a/m-NSCLC with unknown KRAS mutation, was predicted based on associated PFS. Model performance was measured using restricted mean survival time relative differences (ΔRMST).RESULTS: In KRYSTAL-1, Kendall’s tau was 0.65 (95%CI: 0.50-0.77), confirming moderate association. The observed OS in KRYSTAL-1 was well-predicted by the model (ΔRMST +1.8%). In the external validity check, model predictions were very similar to the observed SAPPHIRE docetaxel OS (ΔRMST -5.6%).
CONCLUSIONS: The individual-level predictive surrogacy model performed well in predicting OS in pre-treated KRASG12C-mutated a/m-NSCLC population, even where the target population differed slightly from the training data. The model predictions will be useful in predicting OS where only PFS data are available.
Conference/Value in Health Info
Value in Health, Volume 27, Issue 12, S2 (December 2024)
Code
MSR188
Topic
Clinical Outcomes, Methodological & Statistical Research
Topic Subcategory
Relating Intermediate to Long-term Outcomes
Disease
No Additional Disease & Conditions/Specialized Treatment Areas, Oncology